31 results about "Anti atherogenic" patented technology

A method of assessing the likelihood that a person who is asymptomatic for coronary artery disease does in fact have the disease is disclosed. The levels of an atherogenic protein and acute phase reactant and optionally of anti-atherogenic protein for an individual are obtained and compared to one or more cut-points related to those substances and, based on the comparison(s), an assessment is made of the likelihood that the individual has coronary artery disease. The atherogenic protein may be OxLDL, the acute phase reactant may be C-reactive protein or fibrinogen, and the anti-atherogenic protein may be HDL.

The invention provides new application of indole-3-carbinol, diindolylmethane and derivatives thereof to preparation of a medicine for preventing and controlling atherosclerosis (AS). The indole-3-carbinol, diindolylmethane and derivatives thereof have obvious effects of resisting oxidation and improving endothelial functions, can ensure that the expression and proportion of all vaso-active substances in a human body are normal and the endothelial functions can be recovered normally, and have the good effects of reducing blood fat, and resisting AS. Meanwhile, the active ingredients of the used small molecule medicines can be obtained easily, and the indole-3-carbinol, diindolylmethane and derivatives thereof are low in price, have stable performance and are convenient to store and transport, and have wide application prospect.

A lipid-lowering tea and a production method relate to the production process of bagged tea. The invention mainly comprises raw hawthorns, cassia seeds, lotus leaves and black tea. The invention can obviously inhibit the increase of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and atherosclerosis index (CAI) of serum, improve the high-density lipoprotein cholesterol (HDL-C) and anti-atherogenic index (AI), prevent fatty liver degeneration, slow and inhibit the formation of atherosclerotic plaque. The tea is of food class, which ensures the taste and has the specific effect; long-term tea drinking causes no toxic side effects; besides, the lipid-lowering tea is convenient and can be used in daily life, working, tourism and leisure time, and the user can enjoy health-care in tea drinking.

The invention provides a total extract for a mulberry leaf prescription as well as preparation and usage thereof. The total extract for the mulberry leaf prescription mainly comprises 5%-95% of polysaccharide, 1%-90% of saponin, 1%-90% of flavonoid, 1%-90% of volatile oil and 1%-90% of alkaloid. On the basis of inheritance of traditional Chinese medicine essence, active ingredients for the prescription are extracted by the inventor according to the modern science and technology for preparing the conventional preparation convenient for patients to take. Lipid reduction, depressurization, blood glucose reduction, immune adjustment, liver injury and tumor resistance experiments on animals prove that the tested medicine has multiple pharmacological activities such as lipid reduction, depressurization, blood glucose reduction, immune adjustment, anti-atherogenic ability, liver protection, tumor resistance and the like and does not show an obvious toxic and side effect.

Embodiments of the invention are directed to improved discrimination of protective (anti-atherogenic) HDL from atherogenic or non-protective (NP) HDL. The methods, systems and computer program products determine protective high density lipoprotein particle (HDL-P) numbers. The methods include obtaining concentration measurements of at least twenty subpopulations of HDL-P subclasses in a blood plasma or serum sample and calculating a protective HDL-P number using (i) a defined subset of the obtained HDL-P concentration measurements or (ii) a zero or defined weighting factor below 1 for HDL-P concentration measurements for HDL subclasses associated with particle sizes above about 11 nm.

The invention disclosed the application of isosteviol in medicine preparing process. The application refers to its application in preparing drugs for regulating blood fat and in preparing anti-atherogenic agent. The application shows that isosteviol can be used as new lipid regulating agent and antiatherogenic agent which is of positive significance for preventing coronary atherosclerotic heart disease and stroke.

The present invention relates to the use of a single-cell protein material (SCP). The SCP material lowers the concentration of cholesterol in plasma, and triglycerides in the liver. SCP also induces a favourable change in the fatty acid pattern, and lowers the concentration of homocysteine in plasma. A preferable embodiment of the invention relates to the use of SCP as an anti-atherogenic and cardio protective agent, either given as a pharmaceutical or as nutritional composition, e.g. as a functional food.

The invention provides a composition consisting of alisol A and alisol A24-acetic ester and application thereof, wherein weight ratio of the composition consisting of the alisol A and the alisol A24-acetic ester is between 1: 0.02 and 1: 50. The invention provides a medicine for treating hyperlipidemia diseases, atherosclerosis diseases or fatty liver diseases by modern medical theory so as to satisfy needs for clinical application. The invention has the advantages that people taking the composition consisting of the alisol A and the alisol A24-acetic ester for a long time do not have abnormal rise of liver transaminase, intrahepatic fat deposit, or increase of liver volume and/or weight. The creativity of the invention lies in that through a systematically study of the specific mixture ratio of the alisol A and the alisol A24-acetic ester, the curative effect of decreasing blood-fat, resisting atherosclerosis and treating fatty liver can be improved, and toxic and side effect can be reduced.

The invention relates to the field of natural medicines, and particularly relates to use of beta-elemene and derivatives thereof in preventing atherosclerosis, and in particular relates to an application in preparation of medicines for treating atherosclerosis. Test results show that beta-elemene and derivatives can remarkably reduce the atherosclerotic plaque area in the coronary artery of an animal model, and meanwhile has remarkable improving effect on two key links in development process of atherosclerosis: adhesion of leukocyte and endothelial cells and peroxidation of lipids. Expression of adherence factors closely related to atherosclerosis can be reduced, so that peroxidation damage of endothelial cells in vitro and in vivo caused by high fat and H2O2 is avoided.

The invention discloses a health food for assisting lipid-lowering, thrombolysis, and anti-arteriosclerosis and a preparation method thereof. It comprises Gynostemma pentaphyllum, natto and auxiliary materials. film, packaging. For the first time, it provides a health food that is non-toxic to the human body and has no side effects. It can assist in lipid-lowering thrombolysis and anti-arteriosclerosis. Regular consumption has dual health effects of regulating blood lipids, assisting in dissolving thrombus and inhibiting thrombus formation.

The invention discloses an application of naringin in preparing medicaments for curing atherosclerosis. Tests prove that the naringin can decrease level of serum cholesterol, inhibit cholesterin on arterial vascular walls from depositing, obviously decrease level of serum TC, TG, LDL-C, remarkably raise level of serum HDL-C, improve activity of serum SOD and increase level of NO, obviously decrease level of MDA, effectively prevent atheromatous plaques from being formed or damaged, and have the obvious function of curing atherosclerosis.

The invention discloses an Artemisia argyi hyperthermia patch and a preparation method thereof. The hyperthermia patch of the invention is composed of natural pure Chinese medicine powder packs, and can continuously release far-infrared and negative ions when the temperature changes; The thermoelectric stimulation effect of microcurrent can effectively improve blood circulation, relieve muscle fatigue, activate cells to promote metabolism, dredge meridians, dispel wind and dampness, relieve pain and cold, and enhance the body's resistance to disease; it can effectively promote the penetration of ingredients, activate blood and dredge collaterals , dissipating blood stasis, relieving pain, anti-cancer, promoting blood circulation and removing blood stasis, anti-arteriosclerosis, while stimulating human blood circulation, activating nerve cells, and eliminating edema.

The invention relates to an application of Chukrasone B in preparing medicines for treating atherosclerosis, wherein the Chukrasone B has the effect of preventing atherosclerosis by adjusting blood fat and protecting endothelial cells. Medicines prepared by Chukrasone B for treating atherosclerosis has a better curative effect to atherosclerosis, and can be used for treating atherosclerosis of human or animals. The use of the Chukrasone B in preparing medicines for treating atherosclerosis provided by the invention is disclosed for the first time. As the framework type belongs to a brand-new framework type, and the inhibiting activity of the Chukrasone B to atherosclerosis is unimaginably strong, the probability of giving any enlightenment by other compounds does not exist. The Chukrasone B has remarkable substantial characteristics and meanwhile has a remarkable progress for treating atherosclerosis.

The invention relates to a salvianic acid A pharmaceutical composition and a preparation method thereof. Salvianic acid A can be dissolved in water, but the preparation of the salvianic acid A has poor stability, is easy for oxidization, is sensitive to light and heat, and causes content reduction and impurity increase, and the guarantee on the stability is a technical problem. The salvianic acid A pharmaceutical composition comprises the salvianic acid A, a pharmacological allowable pH adjusting substance, a stabilizing agent and an excipient. The salvianic acid A in the salvianic acid A pharmaceutical composition has the concentration of 0.5-2,000mg. The weight part of the pH adjusting substance is the adding dosage when a pH value is adjusted to 2.5-7.5, and the stabilizing agent in the salvianic acid A pharmaceutical composition has the concentration of 1mg-0.5g. The salvianic acid A pharmaceutical composition is used as an injection with the effects of protecting the cardiac muscle, promoting blood circulation, removing blood stasis, resisting bacteria, eliminating inflammation, strengthening body immunity, resisting atherosclerosis, reducing blood fat, resisting platelet aggregation, resisting thrombosis, expanding the coronary artery, treating liver injury, resisting cerebral ischemia injury, resisting tumors, and the like and a therapeutical effect on pulmonary heart disease, psoriasis, altitude disease, and the like.

The invention discloses a lymphocyte antigen 96 protein-activated blocker and an application thereof. The blocker comprises tripterine and can be used for preparing drugs or pharmaceutical compositions for treating obesity, diabetes and an acute lung injury and resisting inflammation and atherosclerosis. The lymphocyte antigen 96 protein-activated blocker can be combined with a hydrophobic region combined with MD2 protein, activation of the MD2 protein is inhibited, combination of an MD2 activator and LPS and MD2 can be inhibited and inflammatory reaction is blocked.

This invention relates to a biological oil composition, preferably obtained from a copepod, most preferably the copepod Calanus finmarchicus and the use thereof to prevent or treat formation of atherosclerotic plaques and hence development of coronary heart disease. The composition comprises the same marine n-3 polyunsaturated fatty acids (PUFAs) generally regarded as being responsible for the anti-atherosclerotic effect of marine oils, namely EPA (C20:5n-3 eicosapentaenoic acid) and DHA (C22:6n-3 docosahexaenoic acid). However, quite unexpectedly, it has been found that the oil composition of the present invention has a remarkably higher ability to prevent formation of atherosclerotic plaques than what can be attributed to EPA and DHA alone, and moreover, unlike EPA and DHA alone it has a notable blood cholesterol lowering effect.

This invention provides methods of decreasing apolipoprotein B-containing lipoprotein and of treating atherosclerotic diseases and dyslipidemic diseases by reducing plasma phospholipid transfer protein activity, and methods of identifying chemical compounds for use in such treatments.

This invention includes a composition of Agastache rugosa and tilianin obtained by separation-purification for anti-inflammation and anti-atherosclerosis, and more particularly, an extract of Agastache rugosa and tilianin obtained therefrom by separation-purification which are effective in preventing and treating not only inflammatory diseases but also atherosclerosis related to inflammatory responses and disease in the circulatory system caused by atherosclerosis because they are excellent in inhibiting the activity of complement systems as a factor of inflammatory responses, the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecular-1 (VCAM-1), and the production of nitric oxide (NO). They can also significantly reduce the development of atherosclerosis due to the inflammatory response.

The invention relates to application of Volvalerelactones A to preparation of a drug for treating atherosclerosis. Volvalerelactones A can achieve the atherosclerosis resisting effect by regulating blood lipids and protecting endothelial cells. The atherosclerosis-resisting drug prepared from Volvalerelactones A has a good treatment effect on atherosclerosis and can be used for resisting atherosclerosis of human or animals. The invention discloses the application of Volvalerelactones A to preparation of the drug resisting atherosclerosis for the first time, as the skeleton type is a brand-new skeleton type, Volvalerelactones A has unexpected inhibitory activity for atherosclerosis, it is impossible to reveal the clue through other compounds, and Volvalerelactones A has outstanding substantive advantages and makes great progress in resisting atherosclerosis.

The invention discloses an application of Sarcaboside B in the preparation of medicines for treating atherosclerosis. The Sarcaboside B can play a role in resisting the atherosclerosis by regulating blood lipids and protecting endothelial cells. The medicines for resisting the atherosclerosis, prepared from the Sarcaboside B, have relatively good curative effects on the atherosclerosis and can be used for resisting the atherosclerosis of people or animals. The application of the Sarcaboside B in the preparation of the medicines for treating the atherosclerosis is disclosed by the invention for the first time. As the skeleton type of the Sarcaboside B belongs to a brand-new skeleton type, the Sarcaboside B has unexpected strong inhibitory activity on the atherosclerosis, and the possibility that other compounds provide revelation does not exist. The Sarcaboside B has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for resisting the atherosclerosis.

The invention discloses an application of Chukrasone A in the preparation of medicines for treating atherosclerosis. The Chukrasone A can play a role in resisting the atherosclerosis by regulating blood lipids and protecting endothelial cells. The medicines for resisting the atherosclerosis, which is prepared from the Chukrasone A, have relatively good curative effects on the atherosclerosis and can be used for resisting the atherosclerosis of people or animals. The application of the Chukrasone A in the preparation of the medicines for treating the atherosclerosis is disclosed by the invention for the first time. As the skeleton type of the Chukrasone A belongs to a bran-new skeleton type and the Chukrasone A has unexpected strong inhibitory activity on the atherosclerosis, the possibility that other compounds provide revelation does not exist. The Chukrasone A has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for resisting the atherosclerosis.

The invention studies the inhibitory effect of benserazide hydrochloride on SAP expression through constructing an SAP overexpressed cell model; results show that the benserazide hydrochloride can significantly inhibit the SAP expression quantity of SAP-overexpressed macrophages. In addition, the results not only show that the SAP over-expression can cause the increase in the expression quantity of inflammatory factors TNF-alpha, and a significant difference exists in comparison with a control group, but also show that the SAP over-expression quantity can cause the over-expression of other inflammatory factors such as the TNF-alpha; although the specific effects of SAP in atherosclerosis are unclear, the study can provide a new idea and basis for further clarification of the specific effects and mechanisms of the SAP. In conclusion, the benserazide hydrochloride can significantly inhibit the SAP and TNF-alpha expression quantity of the SAP-overexpressed macrophages, which shows that the benserazide hydrochloride has good potential for improving the atherosclerosis, and a foundation is laid for further study on specific mechanisms and targets of the benzylhydrazine hydrochloride against the atherosclerosis.

The invention discloses a novel drug combination scheme for preventing and treating atherosclerosis, namely coenzyme Q10 and ganoderma lucidum spore oil combined medication. The administration scheme passes confirmation of animal models (suffering from hyperlipidemia and atherosclerosis), and the results show that the effect of the combined medication of the coenzyme Q10 and ganoderma lucidum spore oil for preventing and treating atherosclerosis or hyperlipidemia is obviously superior to that of single administration (coenzyme Q10). The combined medication can achieve the effects of obviously improving the effects of the coenzyme Q10 for preventing and treating the hyperlipidemia and atherosclerosis, reducing the dosage of the coenzyme Q10 and preventing adverse reactions, so that the defects that the curative effect is not obvious during single use of the coenzyme Q10 and side effects are caused due to high dosage of the coenzyme Q10 are overcome.